FDA to Review Zydelig Findings After 6 Trials Discontinued

Gilead Sciences is halting six clinical trials of its cancer medicine Zydelig after reports of serious adverse events, including deaths.

The trials were evaluating the drug in combination with other cancer medicines for chronic lymphocytic leukemia, small lymphocytic lymphoma and indolent non-Hodgkin’s lymphoma.

In the wake of this news, the FDA has issued an alert about the adverse events, adding that it will review findings from the clinical trials.